Zentalis Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ZNTL, updated each market day.
ZNTL AI Sentiment
AI sees no strong directional signal for Zentalis Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Zentalis Pharmaceuticals, Inc. Common Stock
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Sector
Exchange
Market Cap
$275,921,652
Cap Tier
Employees
106
Headquarters
SAN DIEGO, CA
Listed Since
April 3, 2020
Website
ZNTL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ZNTL Volatility
Zentalis Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
